76
Participants
Start Date
June 30, 2012
Primary Completion Date
September 30, 2014
Study Completion Date
July 31, 2016
Eribulin
1.4 mg/m2 IV (Days 1 \& 8), given short (≤15 minute) IV infusion, per institutional standard
Cyclophosphamide
Cyclophosphamide will be given as an IV infusion (600 mg/m2) on Day 1 of each treatment cycle over approximately 30 minutes, or per institutional standard.
Docetaxel
Patients assigned to Treatment Arm 2 will receive docetaxel 75 mg/m2 IV on Day 1 of each treatment cycle every 3 weeks.
Center for Cancer and Blood Disorders, Bethesda
Virginia Cancer Institute, Richmond
South Carolina Oncology Associates, Columbia
Northeast Georgia Medical Center, Gainesville
Woodlands Medical Specialists, Pensacola
Memorial Cancer Institute, Hollywood
Florida Cancer Specialists North, St. Petersburg
Florida Cancer Specialists South, Fort Myers
Tennessee Oncology, Nashville
Oncology Hematology Care, Inc, Cincinnati
Grand Rapids Oncology Program, Grand Rapids
Research Medical Center, Kansas City
Nebraska Methodist Cancer Center, Omaha
The Center for Cancer and Blood Disorders, Fort Worth
Mercy Hospital, Portland
Eisai Inc.
INDUSTRY
SCRI Development Innovations, LLC
OTHER